

Xofigo Market Research and NRC's Training and Experience Requirements for AUs

Ashley Cockerham

Founder & Principal Consultant

Organization of Agreement States Annual Meeting

August 20, 2019



Disclosures

Consultant for:

Bayer HealthCare Pharmaceuticals

Sirtex Medical

NRC Question


Is there a challenge with the current T&E requirements— such as concerns regarding patient access to radiopharmaceuticals— that should be addressed through rulemaking?

YES

Reasons Why


- Geographic distribution limitations of Authorized Users
- Logistical and financial burdens for patients due to additional required office visits

Independent Third-party Market Research for Xofigo




Independent Third-party Market Research for Xofigo

- Patient's health deteriorated
- Cost to the patient was too high
- Patient refused (not due to travel)
- Insurance challenges
- Limited access to RO/NM for administration
- Patient unwilling to travel – no nearby facility



26%

Independent Third-party Market Research for Xofigo




75%

of mCRPC patients recommended for Xofigo are *NOT* referred for Xofigo (among All Physicians)


Reasons for Not Referring Patients for Xofigo Despite Recommendation (Aided)

% mCRPC Patients



N= 278
All MDs


Independent Third-party Market Research for Xofigo



37%
of mCRPC patients referred for Xofigo do **NOT** receive Xofigo (among All Physicians)

Reasons for Not Receiving Xofigo Despite Referral

% mCRPC Patients




29%

All MDs N= 136

20% of physicians indicate availability of nuc med specialist/facility as a top 3 barrier to prescribing Xofigo

Referral Barriers to Xofigo Prescribing and Administration (Aided)

% Uros & Oncs selecting among the top 3 barriers



Summary

- Environment created in which not all patients prescribed Xofigo actually receive it
- Geographic distribution of current Authorized Users does not support treatments
- Revise T&E to eliminate barriers related to limited patient access to radiation oncology/nuclear medicine
 - Create T&E pathway for medical oncologists/urologists